Amgen

AMGN

Market cap $178B

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.

In the latest trading session, Amgen (AMGN) closed at $328.97, marking a +1.44% move from the previous day.

At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.

Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.

Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.

U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 therapies.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a second mid-stage trial in diabetes patients showed that it lowered their blood sugar and weight, the company said on Monday.

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if the medication helps people maintain weight loss.